Retatrutide 20mg

Retatrutide 20mg Overview

Retatrutide is a synthetic peptide investigated for activity across three receptor systems involved in metabolic signalling: the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors.

This combination has led to Retatrutide being described within scientific literature as a triple receptor agonist, distinguishing it from compounds targeting only one or two of these receptor pathways.

Research involving Retatrutide includes receptor pharmacology, preclinical experimental models and human clinical trials examining the biological consequences of combined GIP, GLP-1 and glucagon receptor activity.

This 20mg presentation provides a higher quantity of Retatrutide than our 10mg vial for laboratory research requiring larger quantities of material.

Interlink Peptides supplies Retatrutide 20mg strictly for laboratory and scientific research applications.

Technical Specification

Compound: Retatrutide
Quantity: 1 × 20mg vial
Form: Lyophilised powder
Peptide type: Synthetic GIP / GLP-1 / glucagon receptor triple agonist
CAS Number: 2381089-83-2
Molecular weight: Approximately 4,731 Da
Storage: −20 °C in lyophilised form
After reconstitution: Store refrigerated at 2–8 °C
Certificate of Analysis: Available for this product

Exact analytical specifications should be confirmed using the Certificate of Analysis applicable to the relevant batch.

Research Background

Retatrutide has generated significant research interest because it combines activity involving three distinct receptor pathways within a single molecule.

GIP and GLP-1 are incretin-related signalling systems extensively investigated within metabolic research. Retatrutide additionally incorporates glucagon-receptor activity, enabling experimental investigation of combined signalling across all three pathways.

Published research includes molecular and receptor studies, animal models and human clinical trials. Research areas include glucose and lipid metabolism, energy regulation and wider metabolic signalling.

Researchers should distinguish findings concerning Retatrutide from those involving other incretin-related compounds because differences in receptor activity can substantially affect experimental outcomes.

The existence of clinical research does not make the research material supplied by Interlink Peptides a medicinal product. We make no claims regarding weight loss, appetite reduction, diabetes treatment or other effects in humans.

Interlink Peptides supplies Retatrutide exclusively as a laboratory research material.

Handling & Storage

Store Retatrutide in its lyophilised form at approximately −20 °C, protected from light and moisture.

Once reconstituted with water, store refrigerated at approximately 2–8 °C.

Allow the sealed vial to reach an appropriate laboratory working temperature before opening to minimise condensation inside the vial.

Avoid unnecessary repeated freeze-thaw cycles. Preparation, solvent selection and experimental handling should be determined according to the receiving laboratory’s own validated procedures.

Quality & Testing

Certificate of Analysis documentation is available for Retatrutide.

The COA provides analytical information relating to the tested material. Exact identity, purity and other specifications should be confirmed against the Certificate of Analysis applicable to the relevant batch.

This documentation provides researchers with additional analytical information when evaluating material for laboratory research applications.

Explore our full range of research peptides for laboratory and scientific research applications.

A lower-quantity Retatrutide 10mg presentation is also available for research requiring a smaller quantity of material.

Frequently Asked Questions

What is Retatrutide?

Retatrutide is a synthetic peptide investigated for activity involving the GIP, GLP-1 and glucagon receptors.

Why is Retatrutide described as a triple agonist?

The description refers to its investigated activity involving three receptor systems: GIP, GLP-1 and glucagon.

What is the difference between Retatrutide 10mg and 20mg?

Both presentations contain Retatrutide. The difference is the quantity supplied: this presentation contains 20mg compared with 10mg in the lower-quantity presentation.

How does Retatrutide differ from Tirzepatide?

Tirzepatide is investigated for dual GIP and GLP-1 receptor activity. Retatrutide additionally incorporates glucagon-receptor activity.

Is a Certificate of Analysis available?

Yes. Certificate of Analysis documentation is available for Retatrutide. Researchers should refer to the COA applicable to the relevant batch for exact analytical specifications.

How should Retatrutide be stored?

Store the lyophilised product at −20 °C, protected from light and moisture. Once reconstituted with water, store refrigerated at 2–8 °C.

Research Use Only

Interlink Peptides supplies Retatrutide 20mg strictly for in-vitro laboratory and scientific research purposes.

This product is not intended for human or animal consumption, medical treatment, therapeutic use or clinical application.

We do not provide dosing or administration guidance. Purchasers are responsible for ensuring that their intended use complies with applicable laws and institutional requirements.